Analytical Data
-
Gene name
D2D
- Application
-
Alternative Names
D2D；LEP12；SPRL1A；Late cornified envelope Protein 2D
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5TA82
-
Expression Region
1-110aa
-
AA Sequence
MSCQQNQQQC QPPPKCPPKC TPKCPPKCPP KCPPQCPAPC SPAVSSCCGP SSGSCCGPSS GGCCSSGGGG CCLSHHRPRL FHRRRHQSPD CCESEPSGAS GCCHSSGGCC
-
Molecular Weight
11.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
D2D, or the D2 dopamine receptor, is a critical component in the central nervous system, primarily involved in regulating various neurobiological processes such as mood, cognition, and motor control. Research on D2D recombinant proteins has garnered significant attention due to their potential implications in understanding and treating psychiatric disorders, such as schizophrenia and depression, where dopamine signaling is often disrupted. The ability to produce D2D as a recombinant protein allows for detailed studies on its structure, function, and interactions with other cellular components. This research plays a crucial role in drug development, as targeted therapies that modulate D2D activity can lead to more effective treatments with fewer side effects. Furthermore, the investigation of D2D’s pharmacological properties, such as ligand binding and receptor activation, enhances our understanding of receptor biology and the mechanisms underlying various neuropsychiatric conditions. Ultimately, the study of D2D recombinant proteins contributes to the broader field of neuropharmacology and aids in the quest for novel therapeutic strategies that can transform the management of dopamine-related disorders.
